Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cadonilimab plus Lenvatinib in advanced HCC (SCALE)
NCT06361758Phase 2Withdrawn
- Sponsor
- Zhongshan Hospital, Fudan University
- Start
- May 2024
- Primary completion
- May 2026
- Modality
- Bispecific Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of cadonilimab in hepatocellular carcinoma (HCC), sponsored by Zhongshan Hospital, Fudan University. Planned start May 2024; status: withdrawn.
02
Drugs
cadonilimab
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on NCT06361758.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06361758.